Walvax Biotechnology (SHE:300142) subsidiary Yuxi Walvax Biotechnology obtained drug registration approval from Jordan for its 13-valent pneumococcal polysaccharide conjugate vaccine, according to a Tuesday filing with the Shenzhen bourse.
The vaccine is indicated for infants and children aged six months to five years for the prevention of 13 pneumococcal types, the filing said.
Pneumococcal infections are among the leading causes of death in children and infants worldwide, according to the vaccine manufacturer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments